Gelonghui, January 25 | Peijia Medical-B (09996.HK) announced that for the year ended December 31, 2023, the company's revenue was about 430.0-450.0 million yuan, an increase of about 71.5% to 79.4% over the previous year.
The increase in revenue was mainly due to the following reasons: (i) accelerated commercialization of transcatheter aortic valve replacement products (including first-generation TaurusOne and second-generation recyclable TaurusElite) to further expand the Group's market share; (ii) the Group's existing neurological intervention products (including Tethys intermediate catheters, Jasper intracranial electrolysis spring coils, and SAC balloon expansion catheters) continued to increase market share and significant sales growth; and (iii) the Group was newly approved in 2022 and 2023 Ischemia and pathway products (including Syphonet embolization stents, Fastunnel delivery balloon dilatation catheters, Tethys AS thromboaspiration catheters, DCWire microguides, and FluxCap balloon catheters) have gradually been accepted by more hospitals, thus creating new revenue streams.